Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vaccines

05/08/2021 | 11:47am EDT

By Eric Sylvers

European Union leaders pushed back against President Biden's call to wave intellectual property rights for Covid-19 vaccines, saying exporting more shots would be a faster way to help poor countries struggling to contain the virus.

The EU is ready to discuss the U.S. stance, which the Biden administration voiced earlier this week, when there is a concrete proposal, European Council President Charles Michel said at a summit in Portugal on Saturday.

"We don't think in the short term that it's the magic bullet," Mr. Michel said of the proposal to lift patent protections, which could enable companies in developing countries and others to manufacture their own versions of Covid-19 vaccines.

German Chancellor Angela Merkel also rejected the idea of waiving Covid vaccine patents. She said a waiver wouldn't make more vaccine doses available and countries should protect "the power of innovation" and patent protections. Germany is home to BioNTech SE, which co-developed a vaccine with Pfizer Inc., and CureVac NV, which is running clinical trials for a Covid vaccine.

The Biden administration's embrace of the waiver sent the EU scrambling to explain its plans to help poor countries when the U.S. and Europe are quickly vaccinating their populations. The more the virus spreads, the more likely it is to mutate into a vaccine-resistant strain.

To help countries like India facing a surge in infections and deaths, richer countries should concentrate on increasing vaccine production around the world in facilities already making the vaccine, EU leaders said. Rich countries should also export more vaccine doses, Ms. Merkel and other EU leaders said.

The EU has exported more than 200 million vaccine doses, the same amount that has have been delivered to Europeans, EU Commission President Ursula von der Leyen said this week. The U.S. government has used the Defense Production Act to force private companies to first honor contracts with the government before they meet orders from other companies or countries. The U.S. has stockpiled millions of doses of the AstraZeneca vaccine even though the shot isn't approved for use in the country. On April 26, the Biden administration said it would share as many as 60 million AstraZeneca doses with the rest of the world.

Late last year, India and South Africa proposed waving patents for Covid-19 vaccines, treatments and diagnostics. More than 100 countries have supported the proposal, with the U.S. joining the chorus this week.

Even with the U.S. support, challenges remain before the patent wavier could significantly increase vaccine production. It might take several months to define the details of any plan, with potential sticking points including how drugmakers would transfer technical know-how to manufacturers without vaccine expertise. Six months could pass before plants produce their first doses of a vaccine, according to some public health experts.

Production could also be hampered by the need to fund new machinery and adapt the production process, according to some Covid vaccine manufacturers that have opposed the waiver idea.

Write to Eric Sylvers at eric.sylvers@wsj.com

(END) Dow Jones Newswires

05-08-21 1347ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.17% 8336 Delayed Quote.13.63%
BIONTECH SE -2.96% 229.5 Delayed Quote.181.53%
CUREVAC N.V. -2.05% 56.91 Delayed Quote.-29.80%
DJ INDUSTRIAL -0.21% 33874.24 Delayed Quote.10.91%
DOW JONES AFRICA TITANS 50 INDEX -0.12% 528.25 Delayed Quote.-0.39%
DOW JONES SOUTH AFRICA(ZAR) 0.00% 1885.9 Delayed Quote.6.32%
PFIZER, INC. -1.41% 39.05 Delayed Quote.6.09%
S&P AFRICA 40 INDEX 0.74% 170.6 Delayed Quote.-1.99%
All news about BIONTECH SE
03:12pMODERNAá : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
RE
11:56aEuropean ADRs Edge Higher in Wednesday Trading
MT
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
MT
10:17aBIONTECHá : EMA - Two additional manufacturing sites for BioNTech Pfizer's COVID..
AQ
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
10:03aSIEMENSá : To Provide Technology Support For BioNTech's Vaccine Production Sites
MT
09:08aToday on Wall Street: We shall not be ruled by inflation fears
08:20aSiemens, BioNTech to Expand Vaccine Production Collaboration
DJ
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
AQ
01:02aSECTORAL ASSET MANAGEMENTá : Covid-Vaccine Patent Waiver: Will it Increase World..
DJ
More news
Financials
Sales 2021 12 387 M 14 777 M 14 777 M
Net income 2021 7 065 M 8 428 M 8 428 M
Net cash 2021 7 669 M 9 149 M 9 149 M
P/E ratio 2021 6,80x
Yield 2021 -
Capitalization 46 467 M 55 429 M 55 430 M
EV / Sales 2021 3,13x
EV / Sales 2022 3,10x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 192,39 €
Average target price 148,37 €
Spread / Average Target -22,9%
EPS Revisions
Managers and Directors
NameTitle
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE181.53%57 117
GILEAD SCIENCES, INC.15.09%84 093
WUXI APPTEC CO., LTD.36.51%68 536
REGENERON PHARMACEUTICALS10.54%55 301
VERTEX PHARMACEUTICALS-20.09%48 892
BEIGENE, LTD.28.69%30 775